Kraig Biocraft Laboratories Reports $3.6 Million Net Loss for Fiscal Year 2025

Kraig Biocraft Laboratories, Inc. reported a net loss of $3.6 million for the fiscal year ending December 31, 2025, an increase of 6.6% from the previous year's loss of $3.4 million. The company did not generate any revenue during both fiscal years, maintaining a consistent revenue figure of $0. Operating expenses rose to $3.37 million, up from $3.07 million in 2024, primarily due to increased general and administrative costs and professional fees. General and administrative expenses accounted for approximately $1.96 million, reflecting a 12.1% increase from the prior year, while professional fees surged by 30.6% to $379,218.

In terms of strategic developments, Kraig Biocraft Laboratories made significant strides in its operational capabilities and geographic expansion. The company established a new subsidiary, Prodigy Silk Co., Ltd., in Vietnam, which is expected to enhance its production operations. This move follows a memorandum of understanding signed with the Vietnam Sericulture Association to improve sericulture practices in the region. The company also entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing it to sell up to $10 million in common stock to raise capital for operational needs.

Operationally, Kraig Biocraft Laboratories has focused on enhancing the robustness of its silk rearing operations, with plans to accelerate its hybridization and breeding programs. The company currently employs between 10-14 individuals in the U.S. and between 8-30 in Vietnam, depending on production cycles. The company has also ramped up its research and development efforts, dedicating approximately 13,769 hours to R&D in 2025, a streamlined approach that has reportedly increased throughput and efficacy.

Despite these advancements, the company faces substantial challenges, including a working capital deficit of $8.58 million and a total stockholders' deficit of $7.99 million as of December 31, 2025. The financial statements raise substantial doubt about the company's ability to continue as a going concern, as it has relied on private loans and stock sales to fund operations. Management is actively seeking additional capital and exploring potential acquisitions to bolster its financial position and operational capabilities. The outlook remains uncertain, with management emphasizing the need for successful fundraising and the execution of its strategic plans to achieve sustainable revenues and profitability.